of genetic and environmental factors, which has a similar genetic basis with T2DM. 7 In recent years, genomewide association study (GWAS) has revealed a close relation of the gene single nucleotide polymorphism (SNP) in the genetic susceptibility to T2DM, including TCF7L2, SLC30A8, HHEX, FTO, PPARG, and KCNJ11. 8, 9 GWAS was also applied for candidate genes of pregnant women and found that some T2DM-susceptibility genes were also associated with the increased risk of GDM. 10 Recent studies have reported that the gene polymorphism and expression level of vascular endothelial growth factor (VEGF) are closely related to the pathogenesis of T2DM, as well as its corresponding complications. 11, 12 VEGF gene is located at the p21.3 of chromosome 6, consisting of seven introns and eight exons with a full molecular length of 14 kb. 13 As an endothelial cell-specific mitogen,
VEGF has identified to have various functions, such as promoting endothelial cell proliferation, increasing vascular permeability, and inducing angiogenesis. 14, 15 Actually, a number of factors, including oxidative stress, hypoxia, and inflammatory response, could induce the increase in VEGF expression in the presence of high glucose. 16 In the study by Zhou et al, 17 the serum VEGF levels measured by ELISA were found to be up-regulated in T2DM patients. The significant elevation of serum VEGF expression also constituted a risk factor for the progression of diabetic retinopathy (DR), as indicated by Ozturk et al 18 Additionally, VEGF +936C/T polymorphism contributed to the risk of developing T2DM according to the study of Porojan et al. 19 The polymorphism in the promoter region of VEGF gene was significantly linked to the risk of retinopathy in T2DM patients. 20 More importantly, this genetic variation could dysregulate the levels of VEGF protein expression. 21, 22 Nevertheless, there are little data related to the association of VEGF polymorphisms and its expression with GDM.
Therefore, by screening Tag SNPs with the software Haploview (Broad Institute, Cambridge, MA, USA), we selected five polymorphic loci of VEGF gene, to explore the correlation of VEGF polymorphism and its expression with GDM, which would provide a scientific support and theoretical basis for the early diagnosis, intervention, and individualized treatment of GDM.
| MATERIAL S AND ME THODS

| Ethics statement
This study was approved by the Ethics Committee of Yantaishan
Hospital and conformed to the Helsinki Declaration, 23 and all patients signed the informed consent form prior to the study.
| Subjects
From October 2015 to October 2017, GDM patients admitted to our hospital were recruited for this study and they were given 75 g oral glucose for oral glucose tolerance test (OGTT) at the 24th-28th week of pregnancy. The OGTT results were evaluated by using the diagnostic criteria published by American Diabetes with ratios of absorbance A260 nm/A280 nm between 1.6 and 1.8.
The DNA extracted was cryopreserved at −80°C in a refrigerator. Besides, the genotyping was performed by using the TaqMan assay and the ABI 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). The expression levels of VEGF in peripheral blood of patients were detected by enzyme-linked immunosorbent assay (ELISA) according to the instructions of the detection kit (R&D Systems, Abingdon, UK). The experiment was repeated three times.
| Collection and determination of clinical indicators
General information of subjects was enquired and recorded, including age, recent illness, past medical history, personal history, pregnancy history, and pre-pregnancy weight, and height, blood pressure, and other indicators were also determined. The pre-pregnancy body mass index (BMI) was calculated according to the formula: pre-pregnancy BMI = pre-pregnancy weight (kg)/height 2 (m 2 ). Besides, an automatic biochemical analyzer (HITACHI, Tokyo, Japan) was used to detect the levels of triglyceride (TG), serum total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).
Glucose oxidase method was used to detect the fasting blood glucose, and chemiluminescence method was used to determine the fasting plasma insulin. Homeostasis model assessment (HOMA) was 
| Statistical methods
The 26 . Statistical significance was set at P < 0.05.
| RE SULTS
| General clinical information of subjects
As shown in Table 1 , the subjects in two groups were not statistically different from each other in mean gestational weeks, number of pregnancies, mode of conception, smoking, TG, and TC levels (all P > 0.05).
Compared with the Control group, the patients in GDM group presented significant increases in age, pre-pregnancy BMI, FBG, fasting insulin (FINS), SBP, DBP, LDL-C, HDL-C, and HOMA-IR levels, but had a statistical reduction in HOMA-β level (all P < 0.05). Family histories of diabetes and previous GDM patients, as well as hypertension identified at initial obstetric visit and pregnancy-induced hypertension patients, were significantly different between the groups (all P < 0.05).
| Distribution of genotype and allele frequencies of VEGF polymorphisms
The genotype and allele frequency distribution of the selected population reached the Hardy-Weinberg equilibrium (P > 0.05), suggesting the representative of the population. Post hoc analysis revealed that our sample size had a power more than 0.8. As displayed in CT+TT vs CC, OR = 2.118, 95% CI = 1.486-3.019, P < 0.001; T vs C, OR = 1.894, 95% CI = 1.416-2.532, P < 0.001). However, the genotype and allele frequency distribution of rs2010963, rs3025010, and rs833069 in GDM group was not apparently different from the Control group (all P > 0.05).
| Haplotype analysis of VEGF gene polymorphisms
The linkage disequilibrium analysis revealed one SNP block that includes four SNPs: rs2010963, rs833069, rs2146323, and rs3025010
( Figure 1 ). Six major haplotypes (frequencies more than 0.03) were estimated, and each was compared between the Control group and 
TA B L E 2
The distribution of genotype and allele frequencies within the VEGF gene polymorphisms in subjects from two groups GDM group, as analyzed by the online software SHEsis ( Table 3) . As a result, the distribution of haplotype CAAC, CAAT, CACC, CACT, GACT, and GGCT was statistically different between the GDM group and the Control group (all P < 0.05), among which CAAC, CACT, and GGCT reduced the risk of GDM, while CAAT, CACC, and GACT increased the risk of GDM (all P < 0.05).
| Comparison of VEGF expression levels
As illustrated by Figure 2 , the expression levels of VEGF in GDM patients were significantly higher than controls (P < 0.05). Besides, the subjects with rs3025039 CT+TT genotype had higher VEGF expression levels than those with corresponding CC genotype (all P < 0.05).
However, the different genotypes and alleles of rs2146323, rs2010963, rs3025010, and rs833069 in patients had no observable influence on the expression levels of VEGF (all P > 0.05).
| Logistic regression analysis
The logistic regression analysis was conducted with GDM as the dependent variable, and with general clinical indicators, VEGF SNPs, and VEGF expression level as independent variables, which was demonstrated in genotype of rs3025039, and VEGF expression levels were turned out to be the independent risk factors for GDM, and meanwhile,
HOMA-β was suggested as the independent protective factor for GDM (all P < 0.05).
| D ISCUSS I ON
Through detecting five SNPs withinVEGF gene, we found that subjects carried with AA, CA+AA genotypes, and A allele of rs2146323, and those who carrying CT, TT, CT+TT genotypes, and T allele of rs3025039 had the dramatically increased risk of GDM, which suggested that these two genetic polymorphisms (rs2146323 and rs3025039) in the VEGF gene would be recognized as the susceptible factor for GDM. In agreement, VEGF rs2146323 A allele has been suggested by Ying Zeng et al 27 to increase the risk of DR via a meta-analysis. Besides, the TT genotype of 936C>T (rs3025039) in the VEGF gene was the risk factor for the pathogenesis of metabolic syndrome. 28 However, the resting three polymorphisms (rs2010963, rs3025010, and rs833069) were found unrelated to the risk of GDM in this study. In diabetic patients, previous studies also confirmed that the VEGF rs3025010 and rs833069 polymorphisms had no significant difference in the risk of DR. 20, 29 Interestingly, in South Korean and Japanese populations, rs2010963 was found to be closely associated with the incidence of DR, 21,30 but did not show any associations with DR in the meta-analysis by Lu et al, 31 which could possibly attributed to the interactions of different ethnic genetic and environmental factors between VEGF gene polymorphisms and diseases, leading to the great difference among different populations.
32,33
On the other hand, VEGF gene polymorphisms could induce the abnormal expression of VEGF and then aggravate the disease.
22
After detecting the expression level of VEGF, the dramatically increased serum levels of VEGF were exhibited in GDM patients.
Possibly, the up-regulated VEGF might be directly or indirectly by protein kinase (PKC), advanced glycation end products (AGEs), transforming growth factor-β (TGF-β), and intracellular insulinlike growth factor (IGF) under the condition of high glucose.
34,35
Similarly, the serum VEGF expression level was apparently elevated
and it was correlated to the severity of diabetic polyneuropathy. 36 Further, we also found that the rs3025039 CT+TT genotype carriers had apparently higher VEGF expression levels than rs3025039
CC genotype carriers, while no observable difference was found VEGF expression level to be the independent risk factors for GDM, while HOMA-β to be an independent protective factor for GDM after performing logistic regression analysis. Of note, evidence has pointed out that the incidence rate of GDM would increase with the age of pregnant women, 43 and obesity (especially BMI > 30) or obesity-related insulin resistance plays an important role in the pathogenesis of GDM, 44, 45 showing that the occurrence of GDM is caused by the interaction of many factors, and early screening from many aspects is of great value for the diagnosis and treatment of GDM.
The limitations of the current study include a relatively smaller number of enrolled subjects than previous studies. We will collect more data from a larger sample size in the future and hope to obtain more exact results therefrom.
In summary, we found VEGF rs2146323 and rs3025039 polymorphisms and its expression levels were associated with the risk of GDM. Besides, multiple VEGF loci may affect the pathogenesis of GDM through their interaction with each other, which is of great significance for the clinical assessment and diagnosis of GDM.
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